Suven Life Sciences Limited
SUVEN

Suven Life Sciences Limited

Healthcare Research, Analytics & Technology
Share price
₹269
Market cap
₹7,608 Cr
1Y return
▲ 52%

A clinical-stage biopharmaceutical company engaged in the acquisition, development, and commercialization of novel therapeutics for treating neurodegenerative disorders. Suven Life Sciences operates across research, analytics, and technology platforms to advance its pipeline of investigational drugs targeting diseases affecting the nervous system. The company focuses on bringing innovative treatment solutions to patients suffering from neurological conditions through rigorous clinical development processes.

Recent moves 3

Quant Mutual FundExited
Quant Mutual Fund has dropped from Suven Life Sciences Limited's disclosed shareholder list after previously holding 1.78 percent, indicating either a complete exit or a reduction of its stake to below the 1 percent reporting requirement.
19 Jul 2026
Read more
Sunil SinghaniaDecreased
Sunil Singhania trimmed his stake in Suven Life Sciences Limited from 1.13% to 1.00% through Abakkus Diversified Alpha Fund, selling 1,68,636 shares.
16 Jul 2026
Read more
Jasti Property and Equity Holdings Private LimitedIncreased
Jasti Property and Equity Holdings Private Limited increased its stake in Suven Life Sciences from 65.40% to 69.57% by acquiring 3,17,68,764 shares for ₹437.58 Cr at ₹137.74 apiece through a preferential allotment.
6 Mar 2026
Read more

Track the whales in Suven Life Sciences Limited

Get alerted the moment a top investor buys or sells.

Start 7 days for ₹1